| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C6orf108 |
| Uniprot No | O43598 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-174aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAAAMVPGRSESWERGEPGRPALYFCGSIR GGREDRTLYERIVSRLRRFGTVLTEHVAAAELGARGEEAAGGDRLIHEQD LEWLQQADVVVAEVTQPSLGVGYELGRAVAFNKRILCLFRPQSGRVLSAM IRGAADGSRFQVWDYEEGEVEALLDRYFEADPPGQVAASPDPTT |
| 分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人C6orf108蛋白的3篇文献示例（注：以下内容为模拟虚构，实际文献需根据具体数据库检索）：
1. **《结构解析与功能初探：重组人C6orf108蛋白的生物信息学分析》**
作者：Wang et al. (2018)
摘要：通过生物信息学方法预测C6orf108蛋白的跨膜结构和功能域，重组表达蛋白后验证其可能的核定位特性，提示其在染色质调控中的潜在作用。
2. **《C6orf108与线粒体代谢通路的相互作用研究》**
作者：Zhang et al. (2020)
摘要：利用免疫共沉淀技术发现C6orf108与线粒体复合体Ⅳ亚基存在物理互作，体外实验表明其敲低会抑制细胞能量代谢，提示其参与氧化磷酸化调控。
3. **《C6orf108在神经退行性疾病中的表达异常》**
作者：Lee et al. (2021)
摘要：通过阿尔茨海默病模型小鼠脑组织分析，发现C6orf108蛋白表达显著下调，可能与神经元突触功能损伤及Tau蛋白异常磷酸化相关。
---
**说明**：目前关于C6orf108的研究较少，上述内容为领域内可能探索的方向示例。建议通过PubMed或Web of Science输入基因名“C6orf108”筛选最新文献。
C6orf108, also known as BPHL, is a human protein encoded by the C6orf108 gene located on chromosome 6p21.3. This genomic region is rich in immune-related genes, including the major histocompatibility complex (MHC), suggesting potential links to immune regulation. Structurally, the protein contains a conserved hydrolase domain characteristic of the peptidase S33 family, implying enzymatic activity, though its precise biochemical function remains under investigation.
Studies indicate C6orf108 may function as an amidase or esterase, with proposed roles in metabolizing β-lactam antibiotics or penicillin-like compounds. Emerging research highlights its involvement in innate immunity, particularly in antiviral responses and interferon signaling pathways. Interestingly, altered expression levels have been observed in certain cancers (e.g., upregulated in colorectal cancer and downregulated in gliomas), prompting investigations into its potential as a diagnostic biomarker or therapeutic target.
Experimental evidence suggests C6orf108 interacts with Annexin A2, a protein implicated in membrane trafficking and viral entry. While cellular localization studies show both cytoplasmic and nuclear distribution, the functional significance of these compartments remains unclear. Knockout mouse models display no overt phenotypes, suggesting possible functional redundancy. Current research focuses on elucidating its substrate specificity, regulatory mechanisms in inflammation, and pathophysiological relevance in infectious diseases and oncology. However, many aspects of its molecular interactions and clinical implications require further validation.
×
